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Objectives The goal of this study was to compare the efficacy and safety of second-generation everolimus-eluting stents
(EES) with first-generation sirolimus-eluting stents (SES) in primary percutaneous coronary intervention (PCI) for
acute myocardial infarction (AMI).
Background Drug-eluting stents (DES) in AMI are still feared for possible late and very late stent thrombosis (ST). Newer-
generation DES, with more hemocompatible polymers and improved healing, may show promise regarding in-
creased efficacy of DES with improved safety. However, no randomized trials in AMI are available.
Methods A total of 625 patients with AMI were randomized (2:1) to receive EES or SES in the XAMI (XienceV Stent vs Cypher
Stent in Primary PCI for Acute Myocardial Infarction) trial. Primary endpoint was major adverse cardiac events (MACE)
at 1 year consisting of cardiac death, nonfatal AMI, or any target vessel revascularization. The study was powered for
noninferiority of EES. Secondary endpoints comprised ST rates and MACE rate up to 3 years.
Results The MACE rate was 4.0% for EES and 7.7% for SES; the absolute difference was 3.7% (95% confidence inter-
val: 8.28 to 0.03; p  0.048) and relative risk was 0.52 (95% confidence interval: 0.27 to 1.00). One-year
cardiac mortality was low at 1.5% for EES versus 2.7% for SES (p  0.36), and 1-year incidence of definite
and/or probable ST was 1.2% for EES versus 2.7% for SES (p  0.21).
Conclusions In this all-comer, randomized, multicenter AMI trial, second-generation EES was noninferior to SES, and superiority for MACE
was suggested. ST rate in EES at 1-year was low, but long-term follow-up and larger studies will have to show whether very
late ST rates will also be improved in newer DES. (XienceV Stent vs Cypher Stent in Primary PCI for Acute Myocardial Infarc-
tion [XAMI]; NTR1123) (J Am Coll Cardiol 2012;60:381–7) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.01.073The efficacy and safety of drug-eluting stents (DES) in the
treatment of coronary artery disease is well established.
Restenosis rates have dramatically decreased for both on-
label and off-label indications (1–3). Despite these results,
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2012, accepted January 23, 2012.the concern for increased (late) stent thrombosis is still
present (3–5). This finding may be due to delayed vascular
healing after DES implantation (6,7), probably as a result of
drug and/or polymer reaction. Late coronary endothelial
dysfunction after DES implantation has been reported
previously (8). Because acute myocardial infarction (AMI)
presents the highest possible thrombotic coronary lesions,
DES implantation during primary percutaneous coronary
intervention (PCI) for AMI is still not advocated by many
interventional cardiologists. However, even in this challeng-
ing population, the use of DES has increased over the last
few years, and several randomized studies and large cohort
studies have reported efficacy and safety (9–12).
Newer antiproliferative drugs and more biocompatible
polymers have shown promise in reducing further the rate of
(late) stent thrombosis in patients in stable condition
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data are available on the efficacy and
safety of newer-generation DES in
AMI patients.
In our center, Cypher (Cordis,
Bridgewater, New Jersey), the
sirolimus-eluting stent (SES), has
been the default stent since 2004 in
PCI for all indications, including
acute coronary syndromes. With the
emergence of a second-generation
“limus” DES stent (Xience V [Ab-
bott Vascular, Santa Clara, Califor-
nia], an everolimus-eluting stent
[EES]), a multicenter randomized
trial was designed to compare both
stents in AMI patients (XAMI
[XienceV Stent vs Cypher Stent in
Primary PCI for Acute Myocardial
Infarction]).
Methods
Study design and patient popu-
lation. Between February 2008
and December 2009, consecutive patients presenting with
ST-segment elevation myocardial infarction (STEMI)
treated with primary PCI and fulfilling the inclusion criteria
where included in three large interventional centers in the
Netherlands. To be included, patients had to have STEMI
and be eligible for primary PCI. Patients with non–ST-
segment elevation myocardial infarction (NSTEMI) with
an emergency indication for PCI at admission were also
allowed.
Exclusion criteria were as follows: stent thrombosis of
previous stent or chronic total occlusion as target lesion;
known allergy or intolerance to sirolimus, everolimus, aspi-
rin, or clopidogrel; intubated patient after extensive resus-
citation or shock patients for whom no informed consent
could be obtained; estimated life expectancy 1 year; or
stent size required to treat lesion 3.5 mm (maximum
diameter of SES).
The study was approved by the institutional ethics com-
mittee at each participating center, and written informed
consent was obtained from all patients.
Randomization and blinding. Patients were randomized
2:1 to EES or SES by using a sealed envelope technique,
directly after diagnostic angiography and assessment of
feasibility for stenting. Operators were not blinded to the
allocated stent. An independent Data Safety Monitoring
Board evaluated the study safety after 30-day inclusion of
300 patients, blinded to the allocated stent type. At 1
year, all events were evaluated and adjudicated by an
independent clinical event committee, again blinded to
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
BMS  bare-metal stent(s)
CI  confidence interval
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent
MACE  major adverse
cardiac event(s)
NSTEMI  non–ST-segment
elevation myocardial
infarction
PCI  percutaneous
coronary intervention
SES  sirolimus-eluting
stent(s)
STEMI  ST-segment
elevation myocardial
infarction
TVR  target vessel
revascularizationtreatment assignment.Procedure. All patients were pretreated with intravenous
aspirin and heparin 5,000 IE bolus, and they received
clopidogrel with a loading dose of preferably 600 mg.
Interventions were performed according to local practice in
three high-volume centers by high-volume operators.
Glycoprotein IIb/IIIa receptor blocker use, thrombus
aspiration, and balloon pre-dilation were left up to the
operator. Aspirin was recommended for life, and clopidogrel
for a minimum of 1 year.
The study has a 3-year planned follow-up.
Study endpoints and definitions. The primary endpoint
was major adverse cardiac events (MACE) at 12 months
consisting of any event during follow-up in hierarchical
order: cardiac death, nonfatal reinfarction, or any target
vessel revascularization (TVR).
The secondary endpoints were (sub) acute stent throm-
bosis at 30 days and late stent thrombosis at 1, 2, and 3
years, MACE at 30 days and 2 and 3 years, and all-cause
mortality at 1, 2, and 3 years.
Reinfarction was defined according to recurrent symp-
toms and/or new electrocardiographic changes, with re-
elevation of the creatine kinase concentrations 1.5 times
the previous value with elevation of creatine kinase-
myocardial band, if within 48 h, or 3 times the upper
normal limit if after 48 h from the index AMI. More than
5 times the upper limit of normal creatine kinase was
required for the diagnosis of AMI after bypass surgery.
TVR was defined as any repeat percutaneous intervention
or bypass grafting of the target vessel, and target lesion
revascularization as any repeat percutaneous intervention or
bypass grafting of the target lesion or 5 mm proximal or
distal to the initial stent.
Definite and probable stent thrombosis was defined accord-
ing to the Academic Research Consortium criteria (15).
Statistical analysis. Data collection, handling, and statis-
tical analyses were performed by an independent core
laboratory (Diagram B.V., Zwolle, the Netherlands).
This trial was based on the notion that the performance
of EES would not be inferior to SES in relation to the
primary outcome, MACE at 1 year, with the use of a
pre-specified noninferiority margin and a 95% confidence
interval (CI).
We calculated that a sample size of 600 patients (2:1
randomization) would provide a power of 80% (Farrington
and Manning method). This sample size took into account
an expected 1-year MACE rate of 8% and a noninferiority
margin of 6%, and a 2-sided risk of 0.05. Sample size was
increased to 625 patients (after the pilot phase without any
unblinding of data) to compensate for a small pilot phase of
80 patients, randomized 1:1, to maintain adequate power of
the trial.
Study outcomes were assessed by using both intention-
to-treat and per-protocol analyses. The intention-to-treat
population included all patients who were randomized to
treatment. These results are reported in this paper. The
per-protocol population included all patients who fulfilled
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July 31, 2012:381–7 EES Versus SES in AMIthe inclusion and exclusion criteria and in whom the
randomly chosen stent was placed. A second per-protocol
analysis also excluded the NSTEMI patients in the trial to
confirm consistency of the trial results in true STEMI
patients.
Data are reported as percentages for discrete variables.
Continuous variables are reported as mean SD or median
with 25th and 75th percentiles. Categorical variables were
compared by using the chi-square test or Fisher exact test.
Continuous variables were compared by using the nonpara-
metric Mann-Whitney U test. Kaplan-Meier survival esti-
mates were used to compare time to the first occurrence of
MACE with pair-wise differences assessed by using the
log-rank test.
Results
Patients and baseline characteristics. A total of 625
consecutive patients with AMI were included in 3 large
referral interventional clinics in the Netherlands. Four
percent of patients were included with NSTEMI, treated
with emergency PCI at presentation. All other patients
presented with STEMI. Baseline characteristics are shown
in Table 1. Seven percent of patients presented with Killip
class 1. Diabetes was present in 10% of patients. In the
Netherlands, a dedicated infrastructure exists to directly
refer AMI patients to the catheterization suite of an
interventional center without any interference of a local
hospital, general practitioner, or even the emergency depart-
ment. First medical contact is typically at the patient’s
home, and median time from this first contact to balloon
inflation was only 75 min in this study. At diagnosis, the
ambulance personnel immediately administer both high-
dose aspirin and heparin intravenously; in some regions,
clopidogrel is also given orally.
Procedure. Angiographic and procedural characteristics
are shown in Table 2. More than 50% of patients had
Thrombolysis In Myocardial Infarction flow grade 0 at
presentation and single-vessel disease. Compared with pre-
vious AMI studies, a high percentage of radial access of
50% was used. High-dose clopidogrel loading was admin-
istered in most patients; there was also a high percentage of
glycoprotein IIb/IIIa receptor blocker use and thrombus
aspiration catheter use. No significant differences were seen
in any of the parameters except for more heavy calcification
in the SES group. Medication at discharge is shown in
Table 3.
30-day outcome. One patient was excluded because of
withdrawal of informed consent. Results can be seen in
Table 4. Mortality was low, and all deaths were cardiac
related. Acute stent thrombosis was seen in 1 patient in each
group, and definite and/or probable stent thrombosis at 30
days was low (1.3%). Subacute stent thrombosis was higher
with SES, although it was not statistically significant.
1-year outcome. At 1 year, 1 additional patient withdrew
informed consent and was excluded. This withdrawal re- 9sulted in a clinical follow-up at 1 year of 99.7%. One-year
results are listed in Table 4. The primary endpoint of
MACE, consisting of cardiac death, nonfatal MI, or any
TVR at 1 year, was 4.0% for EES and 7.7% for SES. The
noninferiority criterion for EES was met with an absolute
difference of 3.7% (95% CI: 8.28 to 0.03). MACE
ate was significantly reduced for EES with a p value of
.048 and a relative risk of 0.52 (95% CI: 0.27 to 1.00).
iverging of the MACE-free survival curves can be seen in
igure 1. The cardiac death rate was 1.9% for the total
roup. Individual endpoints of all-cause mortality, cardiac
eath, AMI, and TVR all showed a consistently slightly
igher event rate in the SES group, but this finding was not
tatistically significant.
The overall 1-year definite and/or probable stent throm-
osis rate was 1.8%. The difference between EES (1.2%)
nd SES (2.7%) could be attributed to an early difference at
0 days. Late stent thrombosis rate beyond 30 days and up
o 1 year was identical and 0.5% in each group. At 1 year,
Baseline Characteristics of the PatientsTable 1 Baseline Characteristics of the Patients
Characteristic EES (n  404) SES (n  221) p Value
Male 295 (73.0) 167 (75.1) 0.57
Age (yrs) 61.2 11.3 62.0 11.4 0.39
Killip class I 377 (93.3) 206 (92.8) 0.79
STEMI 387 (95.8) 213 (96.4) 0.72
NSTEMI 17 (4.2) 8 (3.6) 0.72
History
Previous Q-wave MI 6 (1.5) 7 (3.2) 0.24
Previous non–Q-wave MI 17 (4.2) 7 (3.2) 0.52
Previous PCI 17 (4.2) 6 (2.8) 0.34
Previous CABG 1 (0.2) 4 (1.8) 0.06
Previous stroke 10 (2.5) 12 (5.4) 0.06
Risk factors
Smoking 220 (54.5) 122 (55.2) 0.86
Diabetes mellitus 36 (8.9) 25 (11.3) 0.33
Hypertension 119 (29.5) 66 (29.9) 0.92
Family history 172 (42.6) 99 (44.8) 0.59
Renal failure 4 (1.0) 4 (1.8) 0.46
Time (min)
Symptoms to first medical
contact
94 (60–180) 97.5 (60–186) 0.92
First medical contact to balloon 75 (60–103) 75 (61–100) 0.58
Infarct size (peak in U/l)
CK 1,831 1,816 1,923 1,994 0.93
CK-MB 205 180 216 219 0.96
Prehospital anticoagulation/
antithrombotics
Aspirin 85.3 83.1 0.47
Unfractionated heparin 74.6 71.7 0.43
Clopidogrel loading 37.3 34.2 0.45
GP IIb/IIIa blocker
intravenously
5.2 6.8 0.41
Values are n (%), mean  SD, median (range), or %.
CABG coronary artery bypass graft; CK creatine kinase; EES everolimus-eluting stent(s); GP
glycoprotein; MB  myocardial band; MI  myocardial infarction; NSTEMI  non–ST-segment
elevationmyocardial infarction; PCI percutaneous coronary intervention; SES sirolimus-eluting
stent(s); STEMI  ST-segment elevation myocardial infarction.4% of patients were still using clopidogrel, together with
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difference between both groups was seen (data not shown).
Additional per-protocol analysis, including NSTEMI
patients, confirmed robustness of the outcome of the pri-
mary endpoint, with a MACE rate of 3.3% (EES) versus
7.8% (SES) (p  0.01; relative risk: 0.43 [95% CI: 0.21 to
.86]).
According to the protocol analysis, excluding the
Angiographic and Procedural CharacteristicsTable 2 Angiographic and Procedural Characteristics
Characteristic
EES
(n  404)
SES
(n  221) p Value
Target vessel 0.43
RCA 42.3 36.7
LAD 38.6 43.0
RCX 18.8 19.5
Left main 0 0.5
Graft 0.2 0.5
Lesion type 0.44
A 1.2 0
B1 31.4 32.6
B2 34.7 34.9
C 32.7 32.6
Heavy calcification 5.7 11.0 0.02
Severe tortuosity 11.2 9.5 0.52
Ostial lesion 3.5 5.4 0.24
Bifurcation 11.4 15.8 0.12
Visible thrombus 85.1 86.4 0.67
TIMI flow 0.74
0 54.5 57.2
1 6.7 5.0
2 17.8 15.8
3 21.0 22.1
Extent of coronary artery disease 0.54
1-vessel 54.2 49.8
2-vessel 32.7 36.7
3-vessel 13.1 13.6
Access site 0.27
Radial 52.0 56.6
Femoral 48.0 43.4
Periprocedural antithrombotics
Clopidogrel, 300 mg loading 3.2 2.3 0.62
Clopidogrel, 600 mg loading 96.0 97.2 0.46
Overall GP IIb/IIIa blocker 74.5 77.8 0.36
Thrombus aspiration 61.9 63.8 0.64
Stent placement 99.5 99.5 1.00
TIMI flow grade 0 to 2 5.0 6.3 0.47
IABP 1.5 1.4 1.00
Total stent length,
target segment (mm)
25.1 13.5 27.9 17.0 0.09
Maximum stent diameter,
target segment (mm)
3.1 0.4 3.1 0.4 0.54
Additional treatment/other
vessel than target
5.2 5.9 0.72
No. of stents/patient 1.3 0.6 1.4 0.7 0.45
Values are % or mean  SD.
IABP  intra-aortic balloon pump; LAD  left anterior descending; RCA  right coronary artery;
RCX right circumflex artery; TIMI Thrombolysis In Myocardial Infarction; other abbreviations as
n Table 1.STEMI patients (4% of the population) who were in-cluded in the trial also revealed a clear benefit of the EES,
with a MACE rate of 3.5 % versus 7.6 % for SES (p 
0.027; relative risk: 0.46 [95% CI: 0.22 to 0.93]).
Discussion
In this randomized trial, the first-generation DES, the SES
Cypher, was compared with the second-generation EES
Xience V in patients with AMI. The results show very low
MACE rates and low percentages of stent thrombosis at 1
Medication at DischargeTable 3 Medication at Discharge
Medication
EES (%)
(n  404)*
SES (%)
(n  221)* p Value
Aspirin 98.5 98.2 0.75
Clopidogrel 98.5 98.6 1.00
Beta-blocker 83.7 81.9 0.57
ACE-I 45.8 47.1 0.76
AT II blocker 5.2 5.9 0.72
Statin 90.6 90.0 0.82
Diuretics 8.9 14.5 0.03
Insulin 3.5 3.6 0.92
Oral antidiabetic 5.7 6.8 0.58
Calcium antagonist 4.0 5.9 0.28
Anticoagulation 2.5 6.8 0.01
Nitrate 4.5 2.3 0.16
Spironolactone 2.2 5.4 0.03
Digoxin 0 0.5 0.35
*In case of in-hospital mortality, medication was checked at time of death.
ACE-I  angiotensin-converting enzyme inhibitor; AT  angiotensin; other abbreviations as in
able 1.
Clinical Results at 30 Days and 1 Year of Follow-UpTable 4 Clinical Results at 30 Days and 1 Year of Follow-Up
Outcome Total EES SES p Value
30-day follow-up (n  624)* (n  403) (n  221)
Death 10 (1.6) 4 (1.0) 6 (2.7) 0.18
Cardiac death 10 (1.6) 4 (1.0) 6 (2.7) 0.18
Nonfatal MI 1 (0.2) 0 1 (0.5) 0.35
TVR 7 (1.1) 5 (1.2) 2 (0.9) 1.00
TLR 2 (0.3) 1 (0.2) 1 (0.5) 1.00
Stent thrombosis
(definite, probable)
8 (1.3) 3 (0.7) 5 (2.3) 0.14
Acute 2 (0.3) 1 (0.2) 1 (0.5) 1.00
Subacute 6 (1.0) 2 (0.5) 4 (1.8) 0.19
1-year follow-up (n  623)† (n  402) (n  221)
MACE‡ 33 (5.3) 16 (4.0) 17 (7.7)§ 0.048
Death 15 (2.4) 8 (2.0) 7 (3.2) 0.36
Cardiac death 12 (1.9) 6 (1.5) 6 (2.7) 0.36
Nonfatal MI 5 (0.8) 2 (0.5) 3 (1.4) 0.35
TVR 19 (3.0) 10 (2.5) 9 (4.1) 0.27
TLR 7 (1.1) 5 (1.2) 2 (0.9) 1.00
Stent thrombosis
(definite, probable)
11 (1.8) 5 (1.2) 6 (2.7) 0.21
Late (30–365 days) 3 (0.5) 2 (0.5) 1 (0.5) 1.00
*One patient was excluded (withdrawal of informed consent). †In total, by 1 year, 2 patients were
excluded because of withdrawal of consent. ‡Primary endpoint: cardiac death, nonfatal myocardial
infarction (MI), or any target vessel revascularization (TVR). §Noninferiority criterion was met;
absolute difference of3.7% (95% confidence interval:8.28 to0.03; p 0.048) with a relative
risk of 0.52 (95% confidence interval: 0.27 to 1.00).
TLR  target lesion revascularization; other abbreviations as in Table 1.
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July 31, 2012:381–7 EES Versus SES in AMIyear in these very thrombotic lesions. Superiority of the
EES was shown for the primary endpoint, and MACE-free
survival curves are still diverging at 1 year of follow-up.
Robustness of outcome was confirmed with additional
per-protocol analysis.
Study population. The current study represents a medium
mortality risk, all-comer AMI population, illustrated by the
mean peak infarction enzyme levels and comparable to other
trials (12,16). Diabetes was present in only 10% of patients,
which is almost identical to findings from several other Dutch
AMI trials (16,17). Patient characteristics were comparable to
other AMI trials such as the large HORIZONS-AMI (Har-
monizing Outcomes with Revascularization and Stents in
Acute Myocardial Infarction) trial (12) and the PASSION
Paclitaxel-Eluting Stent versus Conventional Stent in Myo-
cardial Infarction with ST-Segment Elevation trial (16), and
higher risk than the Typhoon trial (Trial to Assess the Use of
the CYPHer Sirolimus-Eluting Coronary Stent in Acute
Myocardial Infarction Treated With BallOON Angioplasty)
(10), in which SES were compared with bare-metal stent
(BMS) in patients with AMI. In this study, mortality was low
and similar to our study, but extensive exclusion criteria made
this a low mortality risk population.
Event rates. All-cause mortality and cardiac mortality rates
t 1 year were very low in both arms of our study. This
nding may also reflect the progress over the last few years
n patient treatment. Pre-medication with aspirin and hep-
rin at the patient’s home and direct referral to interven-
ional centers leading to a short “ first contact to balloon”
imes will undoubtedly have an effect on final infarct size
nd mortality. The use of radial access in 50% of cases
affects the risk of bleeding and the morbidity and mortality
related to bleeding complications (18,19). The benefit of
thrombus aspiration was demonstrated in the TAPAS study
Figure 1 MACE-Free Survival at 1 Year
Kaplan-Meier estimates of major adverse cardiac event (MACE)-free survival at
1 year in infarct patients randomized to receive everolimus-eluting stents (EES
[blue line]) or sirolimus-eluting stents (SES [red dashed line]).(17). Thrombus aspiration was used in almost 63% of casesin the XAMI trial. For comparison, in the HORIZONS-
AMI study (12), thrombus aspiration was used in only 11%
of patients. Using these contemporary interventional tech-
niques, DES was associated with a low reintervention rate at
1 year. Overall target lesion revascularization rate in this
trial was only 1.1% at 1 year. In-stent restenosis, as seen in
BMS in 20% to 23% of patients in the TYPHOON and
HORIZONS-AMI studies, may not be benign (20), and
reintervention for in-stent restenosis is also associated with
complication risks.
The entire cohort of patients in our trial was not treated
for STEMI. The inclusion criteria allowed NSTEMI pa-
tients to be randomized to treatment under strict conditions
of indication for emergency PCI at presentation. The
pathophysiology of these very unstable lesions will barely
differ and frequently also reflect a totally thrombotic oc-
cluded vessel in NSTEMI. In our trial, only 4% of patients
with NSTEMI were included and will not prevent compar-
ison of our event rates with other STEMI trials. Per-
protocol analysis, excluding these NSTEMI patients con-
firmed this hypothesis, showing a clear benefit for EES in
MACE rate at 1 year (p  0.027).
Stent thrombosis. The event rate was accompanied by a
low rate of definite and/or probable stent thrombosis. The
rate for SES was 2.7%, and for EES it was 1.2%. In
comparison, rates were 3.1% for paclitaxel-eluting stents in
the largest randomized AMI trial with DES so far, the
HORIZONS-AMI. In that trial, the BMS thrombosis rate
(definite or probable) was 3.4%. Pre-randomization with
heparin and a 600-mg clopidogrel loading dose were inde-
pendent predictors of reduced acute and subacute stent
thrombosis in HORIZONS-AMI, respectively (21). In the
XAMI trial, a very high percentage of patients received both
agents.
The difference in stent thrombosis rates at 30 days was
mainly responsible for the difference at 1 year. Although the
influence of procedural and patient characteristics cannot be
excluded, it has been suggested that the newer polymer
coatings used in second-generation DES, such as the EES,
may have anti-inflammatory properties and may be partly
responsible for reduction in early stent thrombosis.
Emerging data on delayed healing (6,7) and late endo-
thelial dysfunction after stenting with SES (8,22), possibly
involved in (very late) stent thrombosis, has hampered the
use of DES, especially in patients with acute coronary
syndromes because their highly thrombotic lesions are more
prone to stent thrombosis. Despite this finding, randomized
trials and large risk-adjusted retrospective studies have
shown superiority of first-generation DES over BMS up to
several years of follow-up (23,24). Next to a significant
decrease in re-interventions, some studies also indicate
decreased mortality (23), although randomized trials have
not confirmed this finding.
Despite the promising low percentage of stent thrombo-
sis, long-term follow-up will have to demonstrate safety, as
continuing rates of late stent thrombosis have been reported
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EES Versus SES in AMI July 31, 2012:381–7in first-generation DES during the first few years (5,25).
Data on improved vascular healing and endothelialization of
second-generation DES (7,26) provide some incentive for
the hypothesis that in these newer-generation DES, incre-
mental rates of (very) late stent thrombosis may be amelio-
rated, even in this highly thrombotic subset of patients.
Recently, 2-year follow-up data of large randomized all-
comer trials including 20% to 30% of AMI patients were
presented. Very few additional stent thromboses were seen
between 1 and 2 years in the EES stent arms (27–29), as
well as in a subgroup analysis of AMI patients who were not
separately randomized (30). The XAMI trial will conduct a
follow-up up to 3 years to investigate the incidence of very
late stent thromboses.
Study limitations. Despite the fact that this was an all-
comer trial and infarct enzyme levels do not reflect a
low-risk population, clinically unstable shock patients were
less likely to be enrolled, and only 7% of patients were in
Killip class1. The low MACE rate cannot be extended to
the total general AMI population, but patient characteristics
were comparable to most other reported clinical AMI trials
comparing DES and BMS (12,16,17), as discussed
reviously.
The lesions in the SES group were more calcified, and
espite comparable peak enzyme levels in both groups,
edication at discharge shows a higher percentage of
iuretic and oral anticoagulation use in the SES patients. A
mall imbalance between groups with lower ejection fraction
n the SES group at presentation cannot be excluded, but
uantified data on left ventricular function at presentation
r follow-up were not collected.
The primary objective of the XAMI trial was to demon-
trate noninferiority of the EES for MACE. The trial was
ot powered for superiority, but at 1-year follow-up, a
arginally significant better outcome was seen for EES.
ccording to several statistical papers (31,32), superiority
ay be claimed in this case, but a definite verdict is
uestionable. As MACE curves diverge at 1 year, longer
ollow-up may answer this question in the coming years.
he trial was not powered to detect significant differences in
dverse events such as stent thrombosis, which has a low
ncidence. Very large trials are necessary to be adequately
owered for these events. However, our trial has a planned
ollow-up of 3 years, and continuing trends toward differ-
nces in incidence of very late stent thrombosis may be seen
t longer follow-up.
The cardiologists performing the primary PCI were not
linded to the allocated stent type. Such blinding would not
e ethical because each stent type has its own typical
ehavior and handling. Despite the higher profile (due to
hicker stent struts) of the SES, only once did the operator
ave to cross over from the SES to EES to cross the lesion.
our times the EES was crossed over to a nonstudy stent.
owever, analysis of MACE was conducted on an
ntention-to-treat basis and performed by a blinded, inde-
endent clinical event committee.Conclusions
In this contemporary, all-comer, randomized multicenter
AMI trial, low MACE rates were seen at 1 year with the use
of DES in primary PCI in AMI. Although not powered for
superiority, the second-generation EES displayed a signif-
icantly lower MACE rate than the first-generation SES, at
least proving noninferiority and even suggesting superiority.
Stent thrombosis rate in EES was very low, but long-term
follow-up and larger-scale studies will be needed to show
whether the reported continuing stent thrombosis rates
beyond 1 year as shown in first-generation DES will also be
improved in EES.
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